computer-based simulation simcyp Search Results


computer-based simulation  (Simcyp)
90
Simcyp computer-based simulation
Time-course of <t>erlotinib</t> depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.
Computer Based Simulation, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/computer-based simulation/product/Simcyp
Average 90 stars, based on 1 article reviews
computer-based simulation - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
computer-based simulation simcyp  (Simcyp)
90
Simcyp computer-based simulation simcyp
Time-course of <t>erlotinib</t> depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.
Computer Based Simulation Simcyp, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/computer-based simulation simcyp/product/Simcyp
Average 90 stars, based on 1 article reviews
computer-based simulation simcyp - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), ritonavir (●) or ketoconazole (□). Data are representative of three to six individual experiments each performed in duplicate. Error bars represent standard deviation.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Standard Deviation

Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Concentration Assay, Incubation

Half-life ( t 1/2 ), % erlotinib metabolized after 48 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Half-life ( t 1/2 ), % erlotinib metabolized after 48 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), ritonavir, or ketoconazole and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Incubation

Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), efavirenz (●), or rifampin (□). Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Time-course of erlotinib depletion (A) and formation of desmethyl erlotinib (B) in primary cultures of human hepatocytes treated with DMSO (○), efavirenz (●), or rifampin (□). Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Standard Deviation

Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Area under the concentration-time curve for erlotinib depletion and desmethyl erlotinib formation in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Concentration Assay, Incubation

Half-life ( t 1/2 ), % erlotinib metabolized after 8 and 24 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Half-life ( t 1/2 ), % erlotinib metabolized after 8 and 24 hours, M/P to AUC ratio, T max of desmethyl erlotinib, and apparent intrinsic clearance (CL int, app ) of erlotinib in primary cultures of human hepatocytes treated with vehicle (DMSO), efavirenz, or rifampin and incubated with erlotinib (5 μ M)

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Incubation

Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, ritonavir, or ketoconazole. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, ritonavir, or ketoconazole. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Comparison

Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, efavirenz, or rifampin. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Predicted human hepatic or oral clearance (CLhep or CLoral) of erlotinib from primary cultures of human hepatocytes treated with DMSO, efavirenz, or rifampin. *P < 0.05 versus DMSO; nonparametric Friedman analysis of variance followed by Dunn’s multiple comparison test.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Comparison

The parameters used for the prediction of hepatic clearance and the comparisons of observed and predicted CL oral values for erlotinib with prediction errors Observed CL oral values (1.9, 3.3, 1.1, 5.3, 5.75, 4.08) were obtained from literature ( N = 6) ( Messersmith et al., 2004 ; Miller et al., 2007 ; Rudin et al., 2008 ; van Erp et al., 2009 ; Padda et al., 2012 ). Predicted CL oral values (0.853, 0.696, 0.997, 0.793, 0.651, 0.668) were obtained from six different vehicle-treated human hepatocytes.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: The parameters used for the prediction of hepatic clearance and the comparisons of observed and predicted CL oral values for erlotinib with prediction errors Observed CL oral values (1.9, 3.3, 1.1, 5.3, 5.75, 4.08) were obtained from literature ( N = 6) ( Messersmith et al., 2004 ; Miller et al., 2007 ; Rudin et al., 2008 ; van Erp et al., 2009 ; Padda et al., 2012 ). Predicted CL oral values (0.853, 0.696, 0.997, 0.793, 0.651, 0.668) were obtained from six different vehicle-treated human hepatocytes.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques:

Recovery of ritonavir-mediated inhibition (top) and efavirenz-mediated induction (bottom) of erlotinib metabolism in primary cultures of human hepatocytes. Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Journal: Drug Metabolism and Disposition

Article Title: Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer

doi: 10.1124/dmd.113.052100

Figure Lengend Snippet: Recovery of ritonavir-mediated inhibition (top) and efavirenz-mediated induction (bottom) of erlotinib metabolism in primary cultures of human hepatocytes. Data are representative of three individual experiments each performed in duplicate. Error bars represent standard deviation.

Article Snippet: Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Techniques: Inhibition, Standard Deviation